Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...
H&R Block (NYSE:HRB) – The tax preparation services company reported fourth-quarter fiscal revenue of $1.063 billion and earnings per share of $1.89, exceeding forecasts of $1.028...
Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66 million, a 190...
U.S. index futures rose slightly in Thursday’s pre-market trading, driven by signs of easing inflation and a rebound in stocks after a week of heavy global sell-offs. Positive inflation data and...
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech...
REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...
Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology1, dermatology and...
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.42 | 3.92523364486 | 10.7 | 11.2 | 10.7 | 81195 | 11.03371703 | CS |
4 | -0.94 | -7.7943615257 | 12.06 | 12.06 | 10.56 | 82823 | 11.24638392 | CS |
12 | -0.88 | -7.33333333333 | 12 | 13.2 | 10.5 | 105786 | 11.82351272 | CS |
26 | -4 | -26.455026455 | 15.12 | 15.3 | 10.5 | 143790 | 12.85740394 | CS |
52 | 1.98 | 21.6630196937 | 9.14 | 18 | 8 | 156426 | 13.75682011 | CS |
156 | 1.62 | 17.0526315789 | 9.5 | 18 | 5.2 | 116736 | 12.14731986 | CS |
260 | 1.62 | 17.0526315789 | 9.5 | 18 | 5.2 | 116736 | 12.14731986 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.